Mike Doustdar

GLP-1 drugs: clinical trends, safety, and market shifts

327 clusters · 1186 sources · last updated 1 day ago

Latest: GLP-1 medication usage impacts nutrition trends and various business sectors

The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, and neurodegenerative health. Recent findings suggest thes

Expanding therapeutic uses and regulatory concerns for GLP-1

38 clusters · 164 sources · last updated 4 days ago

Latest: Semaglutide research explores broader benefits and drug metabolism effects

Medical research continues to expand the therapeutic potential of GLP-1 receptor agonists like semaglutide and tirzepatide. While semaglutide is widely used for weight loss and diabetes, new evidence suggests it may slow

Novo Nordisk pivots strategy to counter patent cliff

112 clusters · 548 sources · last updated 10 days ago

Latest: Novo Nordisk faces intense competition in obesity drug market

Novo Nordisk is implementing a strategic reset to address long-term growth concerns and the looming patent expiration of semaglutide in the early 2030s. To diversify its portfolio and counter competition from Eli Lilly,